Gurnet Point Capital
Gurnet Point Capital is a Cambridge-based private equity firm founded in 2015 that invests in de-risked life sciences companies across biopharmaceuticals, diagnostics, and innovative healthcare services, operating as the life sciences arm of the B-FLEXION investment platform.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Gurnet Point Capital does
Gurnet Point Capital is a private equity firm founded in 2015 and headquartered in Cambridge, Massachusetts, that invests in de-risked life sciences companies. The firm operates as the dedicated healthcare and life sciences investment arm of the B-FLEXION platform, which also fields investment partnerships across credit, real estate, and other strategies. Through B-FLEXION Life Sciences, Gurnet Point targets biopharmaceuticals, diagnostics, and innovative healthcare services with concentrated equity positions in commercial and near-commercial assets.
Its portfolio spans commercial-stage biopharma (Paratek Pharmaceuticals and its FDA-approved antibiotic Nuzyra/omadacycline; Radius Health in osteoporosis; Stallergenes Greer in allergen immunotherapy), specialty drug delivery (Corium International, including the Corplex Donepezil transdermal Alzheimer's program), diagnostics (Naveris), and specialty care services (Allergy Partners). The firm has executed multiple control and take-private transactions since 2017, including Innocoll Holdings ($209M), Corium International ($504M, later consolidated via a 2023 tender offer at $12.50 per share for ~86.21% of shares), Radius Health ($890M), and a $462M joint acquisition of Paratek Pharmaceuticals with Novo Holdings. The firm is led by founder Ernesto Bertarelli, with CFO and Operating Partner Robert Gagnon and principals Travis Read and Anne Stone.
Gurnet Point generates revenue via the standard private equity model — management fees on committed/invested capital within its dedicated life sciences mandate plus realized carried interest on successful exits — rather than through product pricing or subscription SaaS mechanics. As a privately held GP with 1–10 employees, the firm relies on co-investment partners (notably Novo Holdings) and the broader B-FLEXION operational backbone to underwrite, finance, and manage portfolio companies across geographies.
Gurnet Point Capital firmographics
Firmographics- Name
- Gurnet Point Capital
- Website
- https://gurnetpointcapital.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Gurnet Point Capital is a Cambridge-based private equity firm founded in 2015 that invests in de-risked life sciences companies across biopharmaceuticals, diagnostics, and innovative healthcare services, operating as the life sciences arm of the B-FLEXION investment platform.
- Ownership category
- akta.pro rank
Gurnet Point Capital industry classification
Industry- Product category
- Private Equity
- SIC
- Investors, Nec (6799)
- akta.pro primary industry
- Core Infrastructure Funds (Transport, Social, Digital, Utilities) (FSANAEAA)
Keywords
Where Gurnet Point Capital is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Gurnet Point Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
Gurnet Point Capital product offering
Product offeringCore offering
No verifiable core offering details are available in the supplied source material for Gurnet Point Capital.
Product overview
Gurnet Point Capital is a private equity firm that seeds, acquires, and builds investment partnerships in transformative industries, with targeted investment across biopharma, diagnostics, and innovative healthcare services through B-FLEXION Life Sciences. The firm's portfolio consists of acquired biopharmaceutical and healthcare companies rather than a unified product platform. Key portfolio companies include Paratek Pharmaceuticals (acquired for $462M with FDA-approved antibiotic Nuzyra), Corium International (transdermal drug delivery specialist with Corplex Donepezil), Radius Health (bone health therapies), Naveris (diagnostics), Stallergenes Greer (allergen immunotherapy), and Allergy Partners (allergy treatment network). These operate as independent portfolio companies under the investment firm's umbrella.
Differentiator
Problem solved
Functional benefit
Gurnet Point Capital technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gurnet Point Capital partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights3 records
Gurnet Point Capital competitors and assessment
Company assessmentDirect peers
- Patient Square Capital: Healthcare-focused private equity firm investing in de-risked life sciences and healthcare services companies. Direct peer given overlapping strategy of partnering with management on take-privates and growth investments in mid- and large-cap healthcare.
- Avista Capital Partners: Healthcare-dedicated private equity firm with a long track record of biopharma, pharma services, and medtech investments. Comparable to Gurnet Point in targeting later-stage, de-risked healthcare assets with operational improvement theses.
- Linden Capital Partners: Healthcare-focused middle-market private equity firm investing in pharma services, products, and healthcare services. Similar to Gurnet Point in its concentrated healthcare mandate and platform-building approach.
- Ampersand Capital Partners: Private equity firm specializing in life sciences and healthcare, particularly pharma services and diagnostics. Comparable in scale and sector focus to Gurnet Point's B-FLEXION Life Sciences mandate.
- Water Street Healthcare Partners: Healthcare-focused private equity firm investing in healthcare services, life sciences, and medical products. Directly comparable as a sector specialist pursuing buyouts in similarly sized healthcare opportunities.
- Bain Capital Life Sciences: Life sciences-focused investment platform of Bain Capital investing across biopharma, medical devices, and diagnostics. Comparable as a scaled life sciences PE platform with diversified sub-strategies.
- OrbiMed: Healthcare investment firm with private equity, venture, and public strategies across biopharma, medical devices, and diagnostics. Comparable as a sector-dedicated investor with biopharma buyout activity similar to Gurnet Point's.
- Novo Holdings: Denmark-based investment company that co-acquired Paratek Pharmaceuticals with Gurnet Point. Highly comparable as a healthcare-dedicated long-term investor with significant biopharma and life sciences activity.
Broad incumbents
- TPG Capital (Healthcare): Large diversified alternative asset manager with a dedicated healthcare practice that invests in biopharma, healthcare services, and life sciences. Broader in scope than Gurnet Point but overlaps meaningfully in healthcare PE.
- KKR Health Care Strategic Growth: Growth-oriented healthcare investment strategy within KKR covering biopharma, medtech, and life sciences. Comparable as a strategic-growth healthcare investor, though operating as part of a much larger platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Gurnet Point Capital social profiles
Digital presenceGurnet Point Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gurnet Point Capital leadership team
Management profileNumber of profiles
Gurnet Point Capital subsidiaries and ownership
Company hierarchySubsidiaries2 records
Gurnet Point Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gurnet Point Capital M&A and investment
M&A and investmentM&A5 records
Investments12 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gurnet Point Capital
What does Gurnet Point Capital do?
No verifiable core offering details are available in the supplied source material for Gurnet Point Capital.
Is Gurnet Point Capital a public or private company?
Gurnet Point Capital is a private company. It is classified as unknown and is currently operating.
When was Gurnet Point Capital founded?
Gurnet Point Capital was founded in 2015. It employs 1 to 10 people.
Where is Gurnet Point Capital based?
Gurnet Point Capital is headquartered in Cambridge, United States, in the North America region.
Who are Gurnet Point Capital's main competitors?
Direct peers on record are Patient Square Capital, Avista Capital Partners, Linden Capital Partners, Ampersand Capital Partners, Water Street Healthcare Partners, Bain Capital Life Sciences, OrbiMed and Novo Holdings. Broad incumbents are TPG Capital (Healthcare) and KKR Health Care Strategic Growth.
Does Gurnet Point Capital have an API?
No public API is recorded for Gurnet Point Capital.
What industry is Gurnet Point Capital in?
Gurnet Point Capital's product category is Private Equity. Its primary akta.pro industry code is FSANAEAA, Core Infrastructure Funds (Transport, Social, Digital, Utilities). Its SIC code is 6799.